In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
Study findings presented at SABCS 2017 demonstrate that intermediate Oncotype DX scores are prognostic of overall survival for patients with early-stage breast cancer, particularly in younger women with the disease.
The use of flow cytometry has demonstrated usefulness in multiple myeloma recurrence assessment.
An endoscopic imaging tool in development could aid diagnosis of cancer without the delay of pathologic review of tissue sampling and staining.
MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
A new blood test employs a type of DNA signature to locate the presence of tumor in a particular tissue, avoiding the need for invasive diagnostic procedures.
Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.
Patient, Physician Preferences Inform Guidelines for Discussing Molecular Testing in Cancer TreatmentFebruary 16, 2017
Study identifies physician and patient preferences about information, who should communicate this information, and what guidelines should guide these discussions.
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
The simple question: "Would you like to talk about what this means?" can lead to more thorough discussions about scan results and prognoses, better preparing patients to make informed treatment decisions.
Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.
This fact sheet examines pathology reports, including tissue collection methods, the ways in which tissue samples may be processed, and details typically included in such reports.
The recurrence score assay stratifies early stage, estrogen receptor-positive breast cancer by recurrence risk. This study assessed how clinicians use the recurrence score to recommend adjuvant systemic therapy or patients' experiences with testing decision-making.
DNA methylation profiling identified the primary cancer in cases of cancer of unknown primary, informing tumor-type specific treatment that improved overall survival in these patients.
A new technique combines imaging and mathematics to identify aggressive forms of ductal carcinoma in situ (DCIS), or stage 0 breast cancer, from nonaggressive varieties.
Using a computer algorithm to scan images of the esophagus for signs of early esophageal cancer is nearly as accurate as top specialists.
Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.
Breath analysis offers an option for both primary screening and postsurgery monitoring of patients with lung cancer. Exhaled breath has certain carbonyl VOCs that indicate the presence of lung cancer in a process researchers hope will receive FDA approval.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
In patients with cervical cancer who do not have enlarged lymph nodes, SPECT-MRI imaging of their sentinel lymph nodes (SLNs) could assess whether metastases are present.
A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.
The altered metabolism of methionine, tryptophan, kynurenine, and 5-methylthioadenosine can drive the development of glioblastoma. Results also suggest ways to treat the cancer, slow its growth, and precisely elucidate its extent.
Scientists are developing a pill that illuminates only cancerous tumors, improving on current methods that can identify tumors but cannot conclusively determine whether they are cancerous
Disparities Related to Race, Insurance, and Facility Type Affect Use of Genetic Assay in Breast CancerApril 01, 2016
Use and clinical implications of a test commonly used to predict the aggressiveness of early stage ER-positive breast cancer is influenced by patient's race, insurance, and type of facility.
Precision medicine aims to deliver the most appropriate treatment to individual patients; however, biomarker tests that are poorly validated or inappropriately applied could hinder administration of appropriate treatments, and in some cases motivate the use of harmful treatment.
Despite improvements in genomic sequencing technologies, a significant number of medically important genes are within genomic regions in which sequencing lacks the technical accuracy to generate reliable reads.
Unique metabolic biomarkers specific to lung cancer were found through metabolic phenotyping of blood plasma by proton nuclear magnetic resonance (H-NMR), enabling diagnosis of both early-stage and late-stage disease.
A new analysis method for magnetic resonance imaging (MRI) data appears to reliably determine whether patients would need hormonal treatment only or also need chemotherapy.
An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.
Sign Up for Free e-newsletters
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
- Urine Drug Testing Policy Can Assist Opioid Treatment Decisions
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|